Rilpivirine (RPV) is a second-generation non-nucleoside reverse-transcriptase inhibitor used in combination antiretroviral therapy (cART)-naïve and -experienced HIV-positive adult subjects. To evaluate its efficacy and safety in these patient settings, we performed a meta-analysis of randomized controlled trials with available data at 48 and 96 weeks of follow-up.
No takes yet. Share an insight, caveat, or question.
Lazzarin et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: